Q1 EPS Estimate for Corbus Pharmaceuticals Lifted by Analyst

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – HC Wainwright boosted their Q1 2025 EPS estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings per share of ($0.98) for the quarter, up from their previous estimate of ($1.33). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.20) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($5.47) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.14) EPS.

CRBP has been the topic of several other research reports. William Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating on the stock. StockNews.com raised shares of Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Piper Sandler began coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an “overweight” rating and a $35.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Finally, Jefferies Financial Group lowered their price objective on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ CRBP opened at $6.96 on Monday. Corbus Pharmaceuticals has a 1 year low of $6.38 and a 1 year high of $61.90. The company’s 50-day moving average is $9.32 and its 200 day moving average is $18.10. The stock has a market capitalization of $84.77 million, a P/E ratio of -1.48 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.24.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its stake in Corbus Pharmaceuticals by 29.9% in the 3rd quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 5,700 shares in the last quarter. HealthInvest Partners AB boosted its stake in Corbus Pharmaceuticals by 77.9% in the 3rd quarter. HealthInvest Partners AB now owns 69,573 shares of the biopharmaceutical company’s stock worth $1,435,000 after purchasing an additional 30,473 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Corbus Pharmaceuticals by 224.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock worth $1,932,000 after purchasing an additional 64,800 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Corbus Pharmaceuticals by 7.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company’s stock worth $469,000 after purchasing an additional 1,600 shares in the last quarter. Finally, FMR LLC lifted its stake in Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 2,486 shares during the period. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.